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Background. Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in sev-
eral cancer types.
Methods. We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-1, and
PD-L1 and pyrosequencing for assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status in
135 glioblastoma specimens (117 initial resection, 18 first local recurrence). PD-L1 gene expression was analyzed in 446 cases
from The Cancer Genome Atlas.
Results. Diffuse/fibrillary PD-L1 expression of variable extent, with or without interspersed epithelioid tumor cells with membranous
PD-L1 expression, was observed in 103 of 117 (88.0%) newly diagnosed and 13 of 18 (72.2%) recurrent glioblastoma specimens.
Sparse-to-moderate density of tumor-infiltrating lymphocytes (TILs) was found in 85 of 117 (72.6%) specimens (CD3+ 78/117,
66.7%; CD8+ 52/117, 44.4%; CD20+ 27/117, 23.1%; PD1+ 34/117, 29.1%). PD1+ TIL density correlated positively with CD3+ (P
, .001), CD8+ (P, .001), CD20+ TIL density (P, .001), and PTEN expression (P¼ .035). Enrichment of specimens with low PD-L1
gene expression levels was observed in the proneural and G-CIMP glioblastoma subtypes and in specimens with high PD-L1 gene
expression in the mesenchymal subtype (P¼ 5.966e-10). No significant differences in PD-L1 expression or TIL density between initial
and recurrent glioblastoma specimens or correlation of PD-L1 expression or TIL density with patient age or outcome were evident.
Conclusion. TILs and PD-L1 expression are detectable in the majority of glioblastoma samples but are not related to outcome.
Because the target is present, a clinical study with specific immune checkpoint inhibitors seems to be warranted in glioblastoma.
Keywords: glioblastoma, immune checkpoint, programmed death 1, programmed death ligand 1.
Glioblastoma is the most common primary brain tumor in
adults and is associated with high morbidity and poor median
overall survival of 14–17 months across contemporary stud-
ies.1 The current treatment standard for newly diagnosed glio-
blastoma comprises maximal safe resection followed by
combined radiochemotherapy with temozolomide. So far,
experimental treatments with a number of biologicals such
as anti-invasive (eg, cilengitide) and antiangiogenic (eg, cedira-
nib, bevacizumab) agents or inhibitors of specific oncogenic sig-
naling pathways (eg, erlotinib, gefitinib, imatinib, temsirolimus,
everolimus, enzastaurin) have failed to show overall survival
benefits in glioblastoma.2 – 6 Novel treatment concepts based
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on biological insights are urgently needed to improve patient
outcomes.
Glioblastoma has long been recognized as an immunosup-
pressive neoplasm characterized by activation of various im-
mune escape mechanisms including upregulation of
transforming growth factor-b (TGF-b), indoleamine 2,3 dioxyge-
nase (IDO), and programmed death ligand 1 (PD-L1, also known
as B7-H1).7 –9 Emerging evidence suggests differential immuno-
geneity of molecular glioblastoma subtypes with the mesenchy-
mal subtype showing more prominent infiltration by
tumor-associated lymphocytes (TILs) and expression of immune
inhibitory molecules.10,11 Furthermore, loss of phosphatase and
tensin homolog (PTEN), a recurring molecular alteration in glio-
blastoma, has been postulated to induce PD-L1 expression.9
Recently, a novel class of immune modulatory antineoplas-
tic agents, the so-called immune checkpoint inhibitors, has
shown impressive activity with high response rates and durable
tumor remissions in several cancer types including melanoma,
lung cancer, renal cell carcinoma, bladder cancer, and head
and neck cancer.12,13 These agents act by blocking immuno-
suppressive receptors that inhibit effector T-cells and thus facil-
itate the antitumor immune response. Currently, immune
checkpoint inhibitors targeting the programmed death 1
(PD-1) molecule and its ligand PD-L1 are in advanced clinical
development and show compelling activity and favorable tox-
icity profiles across tumor types. PD-1 is a cell surface
co-inhibitory receptor that is expressed on CD3+/CD8+ T-cells
after activation and limits immune response, thus resulting in
functionally “exhausted” T cells.14 Importantly, tumoral ex-
pression of PD-L1, as assessed by immunohistochemistry,
seems to correlate with response to PD-1/PD-L1 inhibitors
and may emerge as a clinically relevant biomarker.13,15 Cumu-
lating evidence, mostly from preclinical studies and experimen-
tal models, indicates a prominent activation of PD-L1 in
glioblastoma.9,16 – 22 However, systematic studies on the ex-
pression of PD-L1 in human tissue samples are lacking so far.
Thus, we set out to characterize PD-L1 expression and its asso-
ciation with other tissue-based and clinical parameters in a
well-annotated retrospective series of human glioblastoma
samples, including matched recurrent tumors to provide a
basis for clinical trials and translational biomarker research.
We also investigated PD-L1 gene expression and its correlation
with patient outcome and molecular glioblastoma subtypes in
the dataset of The Cancer Genome Atlas (TCGA).
Methods
Patients and Materials
Vienna Retrospective Cohort
We retrospectively identified formalin-fixed and paraffin-embed-
ded (FFPE) tumor tissue specimens of 117 adult patients who
underwent neurosurgical resection of newly diagnosed glioblas-
toma at the Department of Neurosurgery, Medical University of
Vienna, between 2006 and 2012 from the Neuro-Biobank of the
Institute of Neurology, Medical University of Vienna. An addition-
al FFPE tumor specimen from the neurosurgical resection of the
first local recurrence was available for 18 patients. Therefore, a
total of 135 specimens (117 newly diagnosed glioblastomas
and 18 matched local recurrences) were used for this study. His-
tological diagnosis of glioblastoma was performed according to
current WHO classification. 23 Clinical data were extracted by
chart review, and survival data were retrieved from the Austrian
Brain Tumor Registry.24,25 The ethics committee at Medical Uni-
versity of Vienna approved the study (Vote 078/2004).
The Cancer Genome Atlas Dataset
We obtained clinical and glioblastoma gene expression data for a
cohort of 446 patients available at TCGA (https://tcga-data.nci.
nih.gov/tcga/). Expression levels of the PDL-1 (CD274) gene
were derived from TCGA Agilent custom design platform and
were represented by a single probe (A_23_P338479). The clinical
data and annotation for MGMT promoter methylation and other
molecular annotation were taken from Brennan et al 2013.26
MGMT Pyrosequencing
For determination of the MGMT promoter methylation status,
six 10 mm sections of newly diagnosed glioblastoma FFPE tis-
sue blocks from the Vienna cohort were cut into an Eppendorf
tube. DNA isolation was performed using the EpiTect FFPE Lysis
Kit (Qiagen), and bisulfite modification was performed using
the EpiTect Fast FFPE Bisulfite Kit (Qiagen). Pyrosequencing
analysis was performed on a PyroMark Q24 MDx (Qiagen) sys-
tem with the therascreen MGMT Pyro Kit (Qiagen).27 In line with
previous publications, specimens with a mean methylation per-
centage ,8% were regarded as MGMT promoter unmethy-
lated, and specimens with a mean methylation percentage
≥8% were regarded as MGMT promoter methylated.27,28
Immunohistochemical Staining
For immunohistochemical staining, FFPE blocks from the Vien-
na cohort were cut into serial 3 mm slices with a microtome.
Immunohistochemistry for CD3, CD8, PD-1, CD20, HLA-DR,
GFAP, and PTEN was performed with a Ventana Benchmark
Ultra immunostaining system, and immunohistochemistry for
PD-L1 was performed using a Dako AutostainerPlusLink immu-
nostaining system. Immunostaining was performed on adja-
cent sections to facilitate comparison of regional distributions
of PD-L1 and PTEN expression and TIL infiltration. Antibodies
and immunostaining protocols are listed in Supplementary
Table S1. FFPE tissue blocks of human non-neoplastic lymph
nodes (TILs) and human placenta (PD-L1) were used as positive
controls. Endothelial cells within the tumor tissue served as in-
ternal positive control for PTEN immunostaining.
Evaluation of Immunohistochemistry
PD-L1 and PTEN Expression
PD-L1 expression was descriptively recorded according to the
cellular and topographical localization, distribution, and inten-
sity of the immunohistochemical signal.
The extent of diffuse/fibrillary PD-L1 and PTEN expression
throughout the tumor tissue was semiquantitatively assessed
according to the following criteria18,29: (i) no positive tumor
areas; (ii) expression in ,25% of non-necrotic tumor area; (iii)
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expression in.25% and,50% of non-necrotic tumor area; (iv)
expression in.50% and,75% of non-necrotic tumor area; (v)
expression in .75% of non-necrotic tumor area.
Presence of epithelioid tumor cells with distinct membra-
nous anti-PD-L1 labeling was recorded only if they constituted
.5% of all tumor cells by semiquantitative assessment in order
to comply with the cutoff used in previous publications.13
Tumor-infiltrating Lymphocyte Density
Density of CD3+, CD8+, PD1+, and CD20+ TIL subsets was
evaluated by overall impression at low microscopic magnifica-
tion (100×). Furthermore, the densities were separately scored
at higher magnification (200x–400x) in predefined regions of
interest, namely: (i) within the glioblastoma tissue; (ii) in peri-
vascular regions; and (iii) in the infiltration zone to the brain pa-
renchyma. Previously published semiquantitative evaluation
criteria were used to describe TIL infiltration density, and TIL
density was judged to be sparse, moderate, or dense.30 The re-
gional distributions of the various TIL subset infiltrates and
PD-L1-positive and PTEN-positive tumor areas were compared
on adjacent tissue sections.
Statistical Analyses
Spearman correlation was applied to analyze correlation of 2 or-
dinal parameters. The chi-square test was used to assess group
differences as appropriate. Overall survival from diagnosis of
glioblastoma to death or last follow-up was estimated using
the Kaplan-Meier limit method. The log-rank test was used to as-
sess group differences. A Cox regression model was used to an-
alyze the association of continuous variables with survival. A
2-tailed significance level (P value) of .05 was applied. Because
of the exploratory and hypothesis-generating design of the pre-
sent study, no adjustment for multiple testing was applied.31 All
statistical analysis was performed with a statistical package for
the social sciences (SPSS) 20.0 software (SPSS Inc).
Results
Vienna Retrospective Cohort
Patients
The patients’ characteristics including clinical baseline parame-
ters, details on administered therapies, and results of MGMT
promoter methylation status testing are listed in Table 1.
PD-L1 Expression
We found prominent PD-L1 staining of variable extent in glioblas-
toma tissues, while the surrounding CNS tissue generally showed
no or only very faint and diffuse focal labeling of the neuropil and
occasional light staining of single and dispersed parenchymal
cells, such as neurons and microglia/macrophages (Fig. 1).
The majority of glioblastoma cases, 103 of 117 (88.0%)
newly diagnosed and 13 of 18 (72.2%) recurrent cases showed
a prominent diffuse/fibrillary expression pattern of variable ex-
tent (Fig. 2). Diffuse/fibrillary PD-L1 expression was typically
found in a patchy distribution throughout the tumor tissue
without accentuation in the perivascular or perinecrotic areas.
Interspersed singular or focally aggregated epithelioid
tumor cells with distinct and strong membranous PD-L1 immu-
nolabeling were found in 44 of 117 (37.6%) newly diagnosed
and 3 of 18 (16.7%) recurrent glioblastomas (Fig. 2). Some
faint diffuse or granular cytoplasmic staining was also observed
in some of these tumors in addition to the membranous signal.
Epithelioid PD-L1+ tumor cells were found exclusively in spec-
imens with diffuse/fibrillary PD-L1 expression.
Table 2 details the results of semiquantitative evaluation of
tumoral PD-L1 expression.
Surrounding brain parenchyma was present and thus evalu-
able for PD-L1 expression in 48 of 117 (41.0%) specimens with
newly diagnosed glioblastoma. Among these, we found some
faint anti-PD-L1 staining of neurons in 32 of 48 (66.7%) speci-
mens, while no neuronal PD-L1 expression was detected in 16
of 48 (33.3%) specimens.
Tumor-infiltrating Lymphocytes and Microglia/
Macrophages
TIL infiltration of variable density was observed in 85 of 117
(72.6%) newly diagnosed and 15 of 18 (83.3%) recurrent glio-
blastoma specimens. TIL infiltration was generally of
sparse-to-moderate density, and TILs were mainly located in
perivascular areas and zones of tumor invasion into the sur-
rounding brain parenchyma (Fig. 3). TILs were only found infre-
quently within the tumor tissue and in perinecrotic areas.
HLA-DR+ microglia/macrophages were distributed diffusely
throughout the tumor tissue. Table 3 shows the results of semi-
quantitative evaluation of the density and distribution of CD3+,
CD8+, CD20+, PD1+, and HLA-DR+ cells.
PTEN Expression
Anti-PTEN immunostaining distinctly labeled the endothelial
cells. Diffuse/fibrillary and membranous PTEN expression of
tumor tissue was variably detected in a patchy pattern
throughout the tumor tissue, without clear-cut accentuation
around necrotic areas or vascular structures.
The semiquantitative distribution of tumoral PTEN expres-
sion was as follows in the newly diagnosed glioblastoma spec-
imens: negative in 27 of 117 (23.1%) specimens; ,25% of
tumor tissue positive in 33 of 117 (28.2%) specimens; .25%
and ,50% of tumor tissue positive in 20 of 117 (17.1%) spec-
imens; .50% and ,75% of tumor tissue positive in 22 of 117
(18.8%) specimens; and.75% of tumor tissue positive in 15 of
117 (12.8%) specimens.
Among recurrent glioblastoma specimens, the semiquantita-
tive distribution of tumoral PTEN expression was as follows: neg-
ative in 8 of 18 (44.4%) specimens; ,25% of tumor tissue
positive in 2 of 18 (11.1%) specimens; .25% and ,50% of
tumor tissue positive in 2 of 18 (11.1%) specimens; .50% and
,75% of tumor tissue positive in 4 of 18 (22.2%) specimens; and
.75% of tumor tissue positive in 2 of 18 (11.1%) specimens.
Comparison of the Spatial Distribution of Tissue-based
Parameters
Comparative evaluation of the spatial distribution of the various
TIL subsets on adjacent sections showed regional overlap of TIL
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infiltration as CD3+, CD8+, and PD1+ TILs were evident in the
same areas in consecutive sections (51/117 [43.6%] newly di-
agnosed and 12/18 [66.7%] recurrent). Regional overlap of TIL
infiltration and PD-L1 expression was infrequently observed
(18/117 [15.4%] newly diagnosed and 6/18 [33.3%] recurrent).
No clear-cut accumulation of PD1+ TILs was observed in the
Table 1. Patient characteristics (Vienna retrospective cohort)
Entire Population (n¼ 117)
n %
Median age at diagnosis of glioblastoma, years (range) 60 (21–80)
Extent of resection
Complete resection of contrast enhancement 58 49.6
Subtotal resection 59 50.4
Median Karnofsky performance score (range) 80% (10%–100%)
MGMT promoter status
Methylated 37 31.6
Unmethylated 62 53.0
Unknown 18 15.4
Steroids before glioblastoma resection
Yes 50 42.7
No 34 29.1
Unknown 33 28.2
Type of postoperative first-line therapy
EORTC/NCIC chemoradiotherapy regimen 93 79.5
EORTC/NCIC chemoradiotherapy regimen plus investigational agent 9 7.7
Other 10 8.5
Unknown 5 4.3
Neurosurgical resection at recurrence
Yes 18 15.4
No 99 84.6
Alive at last follow-up
Yes 37 31.6
No 80 68.4
Median overall survival in months (range) 12 (0–86)
Fig. 1. Low-magnification overview (anti-PD-L1 immunostaining, original magnification ×2) showing prominent and patchy PD-L1 expression
(arrow 1: positive area, arrow 2: negative area) in tumor tissue of a glioblastoma and lack of PD-L1 expression in the adjacent brain
parenchyma (asterisk).
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immediate proximity to PD-L1+ glioblastoma cells or PD-L1+
macrophages.
In most cases, we found no regional overlap of PTEN-
negative and PD-L1 positive areas on adjacent sections. Only
in a minority of specimens (31/117 [26.5%] newly diagnosed
and 6/18 [33.3%] recurrent) did we find discordant expression
profiles with PD-L1 positive areas lacking PTEN expression.
Statistical Analyses
Correlation of Tissue-based Parameters. PD1+ TIL density
correlated positively with CD3+ TIL density (P, .001,
chi-square test), CD8+ TIL density (P, .001, chi-square test),
CD20+ TIL density (P, .001, chi-square test), and PTEN expres-
sion (P¼ .035, chi-square test) but not with density of HLD-DR+
microglia/macrophages (P¼ .215, chi-square test), MGMT pro-
moter methylation status (P¼ .195, chi-square test), membra-
nous PD-L1 expression on epithelioid tumor cells (P¼ .808,
chi-square test), or diffuse/fibrillary PD-L1 expression (P¼
.766, chi-square test).
Diffuse/fibrillary PD-L1 expression was not correlated with
CD3+ TIL density (P¼ .168, chi-square test), CD8+ TIL density
(P¼ .068, chi-square test), CD20+ TIL density (P¼ .516,
chi-square test) or HLA-DR+ microglia/macrophages (P¼ .897,
chi-square test), PTEN expression (P¼ .232, chi-square test), or
MGMT promoter methylation status (P¼ .335, chi-square test).
Furthermore, there was no correlation between presence of ep-
ithelioid tumor cells with membranous PD-L1 expression and
CD3+ TIL density (P¼ .555, chi-square test), CD8+ TIL density
(P¼ .380, chi-square test), CD20+ TIL density (P¼ .093,
chi-square test), HLA-DR+ microglia/macrophages (P¼ .512,
chi-square test), PTEN expression (P¼ .329, chi-square test), or
MGMT promoter methylation status (P¼ .181, chi-square test).
Correlation of Tissue-based Parameters With Clinical Charac-
teristics. There was no correlation between presurgical treat-
ment with corticosteroids and membranous PD-L1 expression
(P¼ .283, chi-square test), diffuse/fibrillary PD-L1 expression
(P¼ .513, chi-square test), density of PD1+ TILs (P¼ .534,
chi-square test), CD3+ TILs (P¼ .889, chi-square test), CD8+
TILs (P¼ .190, chi-square test), CD20+ TILs (P¼ .917,
chi-square test), or density of HLA-DR+microglia/macrophages
(P¼ .542, chi-square test). Further, there was no evident corre-
lation of age (,65 years vs.65 years) and membranous PD-L1
expression (P¼ .612, chi-square test), diffuse/fibrillary PD-L1
expression (P¼ .383, chi-square test), density of PD1+ TILs
(P¼ .945, chi-square test), density of CD3+ TILs (P¼ .418,
chi-square test), density of CD8+ TILs (P¼ .376; chi-square
test), or density of HLA-DR microglia/macrophages (P¼ .758;
chi-square test). However, younger patients (aged ,65 years)
Fig. 2. Diffuse/fibrillary and membraneous PD-L1 expression in glioblastoma. (A–D) (adjacent sections of the same tissue specimen): In
glioblastoma areas with diffuse/fibrillary histomorphology (A: hematoxylin and eosin (H&E) staining, original magnification ×200; Aa: H&E
staining, original magnification×800) and expression of glial fibrillary acidic protein (GFAP; B: anti-GFAP, original magnification×200) we found
prominent diffuse/fibrillary PD-L1 expression (C and D: anti-PD-L1; C: original magnification ×200, D: original magnification ×400). (E –H)
(adjacent sections of the same tissue specimen): In glioblastoma areas with epithelioid tumor cells (E: H&E staining, original magnification
×200; Ee: H&E staining, original magnification ×800) and expression of glial fibrillary acidic protein (GFAP; F: anti-GFAP, original magnification
×200) we found prominent membranous PD-L1 expression and some faint diffuse or granular cytoplasmic staining (G and H: anti-PD-L1; C:
original magnification×200, D: original magnification×400).
Table 2. Programmed death ligand 1 expression in the Vienna
retrospective glioblastoma cohort
Newly Diagnosed
Glioblastoma
(n¼ 117)
Recurrent
Glioblastoma
(n¼ 18)
n % n %
Diffuse/fibrillary PD-L1 expression
None 18/117 15.4 5/18 27.8
≤25% 18/117 15.4 3/18 16.7
.25%, ≤50% 30/117 25.6 2/18 11.1
.50%, ≤75% 39/117 33.3 6/18 33.3
.75% 12/117 10.3 2/18 11.1
Membranous PD-L1 expression
Positive (≥5% of tumor cells) 44/117 37.6 3/18 16.7
Negative (,5% of tumor cells) 73/117 62.4 15/18 83.3
Abbreviation: PD-L1, programmed death ligand 1.
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presented more frequently with sparse and moderate density
of CD20+ TILs than patients aged ≥65 years at diagnosis of
glioblastoma (P¼ .043, chi-square test).
Comparison Between Specimens of First and Second Resec-
tion. The extent of diffuse/fibrillary PD-L1 expression did not
differ between newly diagnosed and recurrent glioblastoma
specimens (P¼ .411, chi-square test; Table 4). Epithelioid
tumor cells with anti–PD-L1 membrane labeling were more
common in initial tumors (9/18, 50%) than in recurrent tumors
(3/18, 16.7%; P¼ .034, chi-square test).
There were no differences between the first and second re-
section for PD1+ TIL density (P¼ .070, chi-square test), CD3+
TIL density (P¼ .237, chi-square test), CD8+ TIL density (P¼
.103, chi-square test), CD20+ TIL density (P¼ .122, chi-square
test), HLA-DR+ microglia/macrophage density (P¼ .085,
chi-square test), or PTEN expression (P¼ .289, chi-square test).
Survival Analyses. Young patient age at diagnosis of glioblas-
toma (16 months for ,65 years vs 11 months for ≥65 years;
P¼ .034, log-rank test), high KPS (4 months for KPS,70% vs
17 months for KPS.70%; P, .001, log-rank test), greater ex-
tent of resection (12 months for subtotal vs 18 months for
total; P¼ .003, log-rank test), and MGMT promoter hyperme-
thylation (,8% for 11 months vs .8% for 18 months; P¼
.002, log-rank test) correlated with overall survival, while den-
sity of PD1+ TILs (15 months for absent vs 15 months for pre-
sent; P¼ .981, log-rank test), presence of diffuse/fibrillary PD-L1
expression (absent 15 months vs present 15 months; P¼ .921,
log-rank test), and presence of epithelioid tumor cells with
membranous PD-L1 expression (15 months for ,5% vs 14
months for .5%; P¼ .724, log-rank test), or presence of
PD-L1- neurons (15 months for negative vs 12 months for pos-
itive; P¼ .533, log-rank test) showed no impact on survival
times (Fig. 4).
TCGA Dataset
Correlation of PD-L1 Gene Expression With Molecular
Glioblastoma Subtypes
In order to see if there was an association between PD-L1 ex-
pression levels and known expression subtypes, we classified
samples into PD-L1 high/low based on median PD-L1 expres-
sion levels. The results in Table 5 showed that there is a statisti-
cally significant difference in the distribution of expression
subtypes between PD-L1 high and low samples (P¼
5.966e-10, Pearson’ chi-square test), with a particularly evident
enrichment of proneural and G-CIMP expression subtypes in the
PD-L1 low group, while the mesenchymal expression subtype is
overrepresented in the PD-L1 high group.
Survival Analyses
Survival analysis using Cox proportional hazard (CPH) regression
was performed in 2 separate subsets of the data. The first sub-
set comprised a total of 446 patients. The MGMT promoter
methylation status was excluded as a covariate because it
was not complete for the 446 patients, and only age and
PD-L1 expression levels were included. PD-L1 had no statisti-
cally significant association with overall survival of patients by
Fig. 3. (A) Dense CD3+ TIL infiltration (magnification ×200). (B) PD1+ TILs infiltrating glioblastoma (magnification ×400). (C) Perivascular
infiltration with CD3+ TILs (magnification×200). (D) CD3+ TILs at the infiltration zone (magnification×200).
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both univariate and multivariate CPH regression (Fig. 4H,
Table 6).
Discussion
PD/PD-L1 interactions are now considered central to the immu-
nological control of cancer. Here we show prominent expres-
sion of PD-L1 by tumor cells in a majority of human
glioblastoma samples. We observed 2 main staining patterns,
which likely relate to the particular and heterogeneous
microarchitecture of glioblastoma as captured in the widely
used descriptive addendum “multiforme.” First, we detected
clear membranous PD-L1 expression with distinct highlighting
of tumor cell surfaces, as seen in epithelial cancers and mela-
noma.15 This expression pattern was mainly found on roundish,
nonfibrillar glioblastoma cells with well-delineated cytoplasm
and cell membranes having some histological similarities
with epithelial cells. Such epithelioid tumor cells are a well-
recognized histological feature of glioblastomas and, in our se-
ries, were interspersed within the tumor tissue as single cells or
focal tumor cell aggregates in 37.6% of newly diagnosed and
Table 3. Density of tumor-infiltrating lymphocytes and microglia/macrophage infiltration per tumor area in newly diagnosed glioblastoma
samples in the Vienna retrospective cohort
n¼ 117 CD3+ TILs CD8+ TILs PD1+ TILs CD20+ TILs HLA-DR+ Microglia
Entire specimen
Sparse infiltration 59/117 (50.4%) 44/117 (37.6%) 34/117 (29.1%) 20/117 (17.1%) 1/117 (0.9%)
Moderate infiltration 16/117 (13.7%) 8/117 (6.8%) 0/117 (0.0%) 6/117 (5.1%) 31/117 (26.5%)
Dense infiltration 3/117 (2.6%) 0/117 (0.0%) 0/117 (0.0%) 1/117 (0.9%) 44/117 (37.6%)
Very dense infiltration 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 37/117 (31.6%)
Total 78/117 (66.7%) 52/117 (44.4%) 34/117 (29.1%) 27/117 (23.1%) 113/117 (96.5%)
Perivascular area
Sparse infiltration 52/117 (44.4%) 41/117 (35.0%) 24/117 (20.5%) 16/117 (13.7%) 9/117 (7.7%)
Moderate infiltration 33/117 (28.2%) 9/117 (7.8%) 3/117 (2.6%) 19/117 (16.2%) 25/117 (21.4%)
Dense infiltration 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 52/117 (44.4%)
Very dense infiltration 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 27/117 (23.1%)
Total 85/117 (72.6%) 50/117 (42.7%) 27/117 (23.1%) 35/117 (29.9%) 113/117 (96.5%)
Within tumor tissue
Sparse infiltration 58/117 (49.6%) 58/117 (49.6%) 34/117 (29.1%) 5/117 (4.3%) 9/117 (7.7%)
Moderate infiltration 6/117 (5.1%) 8/117 (6.8%) 0/117 (0.0%) 0/117 (0.0%) 35/117 (29.9%)
Dense infiltration 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 38/117 (32.5%)
Very dense infiltration 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 0/117 (0.0%) 31/117 (26.5%)
Total 64/117 (54.7%) 66/117 (56.4%) 34/117 (29.1%) 5/117 (4.3%) 113/117 (96.5%)
Infiltration zone
Sparse infiltration 4/46 (8.7%) 9/46 (19.6%) 7/43 (16.3%) 0/43 (0.0%) 13/40 (32.5%)
Moderate infiltration 1/46 (2.2%) 0/46 (0.0%) 0/43 (0.0%) 0/43 (0.0%) 19/40 (47.5%)
Dense infiltration 0/46 (0.0%) 0/46 (0.0%) 0/43 (0.0%) 0/43 (0.0%) 6/117 (15.0%)
Very dense infiltration 0/46 (0.0%) 0/46 (0.0%) 0/43 (0.0%) 0/43 (0.0%) 0/40 (0.0%)
Total 5/46 (10.9%) 9/46 (19.6%) 7/43 (16.3%) 0/43 (0.0%) 38/40 (95%)
Abbreviations: PD1, programmed death 1; TIL, tumor-infiltrating lymphocyte.
Table 4. Comparison of tumor-infiltrating lymphocyte density and programmed death ligand 1expression between newly diagnosed and matched
recurrent glioblastoma specimens (Vienna retrospective cohort)
n¼ 18 Initial Tumor 1,

Recurrence 1
Initial Tumor 2

Recurrence 2
Initial Tumor 1

Recurrence -
Initial Tumor 2

Recurrence 1
Diffuse/fibrillary tumoral PD-L1 expression 12/18 (66.7%) 1/18 (5.6%) 4/18 (22.2%) 1/18 (5.6%)
PD-L1+ epitheloid tumor cells 3/18 (16.7%) 15/18 (83.3%) 0/18 (0.0%) 0/18 (0.0%)
PD1+ TILs 0/18 (0.0%) 15/18 (83.3%) 3/18 (16.7%) 0/18 (0.0%)
CD3+ TILs 10/18 (55.6%) 3/18 (16.7%) 1/18 (5.6%) 4/18 (22.2%)
CD8+ TILs 10/18 (55.6%) 2/18 (11.1%) 4/18 (22.2%) 2/18 (11.1%)
Abbreviation: PD-L1, programmed death ligand 1.
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Fig. 4. A–G: Kaplan-Meier curves in the Vienna retrospective cohort. (A) Overall survival according to age. (B) Overall survival according to Karnofsky
performance status. (C) Overall survival according to extent of resection. (D) Overall survival according to MGMT methylation status. (E) Overall
survival according to membranous PD-L1 expression. (F) Overall survival according to diffuse/fibrillary PD-L1 expression. (G) Overall survival
according to PD-L1 expression in neuron. (H) Kaplan-Meier curve in the TCGA cohort showing overall survival according to PD-L1 gene
expression. All P values are according to the log-rank test.
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16.7% of recurrent glioblastoma specimens.23,32 Second, in
some of these tumor cells, we observed some faint diffuse or
granular cytoplasmic staining in addition to the membranous
signal. This may relate to internalized surface PD-L1 molecules,
as PD-L1 storage and degradation in lysosomes have been de-
scribed in lymphoma models.33 In many cases (88.0% of newly
diagnosed and 72.2% of recurrent glioblastoma cases), a
prominent diffuse/fibrillary PD-L1 immunostaining pattern of
variable extent was seen throughout the tumor tissue. Due to
the intensity of this staining pattern, we believe it likely relates
to membrane-bound PD-L1 on the delicate and intermingled
tumor cell processes that form the pathognomic neurofibrillary
matrix of diffuse astrocytic gliomas. However, distinct labeling
of tumor cell membranes cannot be appreciated in this partic-
ular histological presentation due to the limited spatial resolu-
tion at the light microscopic level. We did not have the
opportunity to investigate the subcellular distribution of PD-L1
(ie, by transmission electron microscopy with immunolabeled
particles). Notably, we observed very faint (or absent) focal
and diffuse staining in the neuropil in tumor-surrounding CNS
tissue parts with occasional light labeling of parenchymal cell
elements. Glial cells (astrocytes, microglia, oligodendrocytes)
and neurons have been shown to express low or undetectable
PD-L1 under basal conditions, but are able to upregulate PD-L1
in response to cytokine release in neuroinflammatory
processes.34,35
The rate of PD-L1-positive cases in glioblastoma found in our
study seems high in comparison with other solid tumor types,
in which 30% of melanoma cases and 25%–36% of non–
small cell lung cancer cases have been found to express
PD-L1 by immunohistochemistry.36,37 Our findings clearly cor-
roborate previous studies in experimental models, suggesting
a prominent involvement of the PD-1/PD-L1 axis in creating
an immunosuppressive microenvironment in glioblastoma.
Taken together, our data and the experimental evidence pro-
vide a strong rationale for clinical trials investigating immune
checkpoint inhibitors in this indication. Of particular interest in
this context are recent reports showing durable therapeutic ef-
ficacy of immune checkpoint inhibition in animal models of glial
brain tumors.8,22 The high prevalence also allows clinical stud-
ies without pretesting the PD-L1 status in the tumor tissue, al-
though post hoc correlation of the extent of PD-L1 expression
with response to treatment may be of interest. Of note, thera-
peutic efficacy of the CTLA4 antibody ipilimumab against mel-
anoma brain metastases has been documented, showing the
feasibility of antibody-mediated immune-checkpoint inhibition
in intraparenchymal CNS lesions.38,39 However, further studies
will be important to investigate in detail the role of the blood-
brain/blood-tumor barrier in drug penetration and intracerebral
efficacy of immune checkpoint inhibitors. Given this uncertainty
and the availability of PD1/PD-L1 inhibitors, these may also be
an option for trials in patients with gliomas.
TIL infiltrates were generally sparse, with some concentra-
tion in the perivascular areas rather than in the tumor tissue.
This finding is well in line with previous observations on the dis-
tribution of TILs in glioblastoma and suggests that TILs might
not be able to readily migrate into the immunosuppressive
tumor microenviroment and arrest in the perivascular
space.40,41
Comparative analysis of newly diagnosed and 18 matched
recurrent glioblastomas showed no clear upregulation or
downregulation of PD-L1 and no significant changes in the den-
sity of PD1+, CD3+, CD8+, or CD20+ TILs over time. Diffuse/
fibrillary PD-L1 expression was common in both newly diag-
nosed and recurrent specimens. Interspersed epithelioid cells
with distinct membranous PD-L1 staining were more common-
ly found in newly diagnosed glioblastoma specimens than in re-
current cases. However, this finding may be influenced by
sampling error and does not necessarily indicate a clinically rel-
evant dynamic in PD-L1 expression.
In our study, we used the noncommercial anti-PD-L1 anti-
body 5H1, which was kindly provided by Dr. Lieping Chen
(Yale University). Specificity of this antibody was confirmed in
a recent publication, while some commercially available
Table 5. Link between expression subtypes and programmed death ligand 1 high/low patients (based on median PDL-1 expression levels) in The
Cancer Genome Atlas dataset (n¼ 446)
Total Molecular Subtype
Unknown
Classical G-CIMP Mesenchymal Neural Proneural
Total 446 16 127 31 126 62 84
PDL-1 high 223/446 (50%) 10/16 (62.5%) 68/127 (53.4%) 7/31 (22.6%) 85/126 (67.5%) 34/62 (54.8%) 19/84 (22.6%)
PDL-1 low 223/446 (50%) 6/16 (37.5%) 59/127 (46.6%) 24/31 (77.4%) 41/126 (32.5%) 28/62 (45.2%) 65/84 (77.4%)
Table 6. Univariate and multivariate survival analyses in 446 TCGA patients
Covariate Univariate Analysis Multivariable Analysis
Coefficient HR 95% CI P Value Coefficient HR 95% CI P Value
Age (continuous) 0.036842 1.038 1.028–1.047 4.88e-15 0.036628 1.037 1.0277–1.047 1.07e-14
PDL-1 expression (continuous) 0.13397 1.143 0.9553–1.368 .144 (NS) 0.034886 1.036 0.8702–1.232 .694 (NS)
Abbreviations: CI, confidence interval; HR, hazard ratio.
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antibodies failed to show reliable PD-L1 labeling.36 Using the
5H1 antibody, a correlation of immunohistochemically detect-
ed PD-L1 expression with response to PD1/PD-L1 inhibition has
been shown in metastatic melanoma.13,15,42 However, re-
sponses to PD-1/PD-L1 inhibitors are observed in a significant
fraction of patients with PD-L1 negative tumor samples, and
the true predictive value of PD-L1 expression is under intense
investigation in ongoing clinical trials.15,37
An association of PD-L1 expression and PTEN loss via PI3K/
AKT pathway signaling has been shown in several studies in
squamous cell cancer, triple-negative breast cancer, pancreatic
cancer, colorectal cancer, and glioblastoma.9,18,20,43 – 45 How-
ever, we did not find a correlation of PD-L1 expression and
lack of PTEN expression at the protein level in our study on
human glioblastoma samples, and this lack of correlation is
consistent with a recent study on melanoma.46 PTEN protein
expression has been shown to correlate poorly with (epi-)
genetic PTEN aberrations in glioblastoma, and further studies
may address whether PTEN methylation, PTEN mutations or
PTEN deletions correlate with PD-L1 expression in glioblastoma
tissue samples.29
Interestingly, we found a highly significant association of
PD-L1 gene expression with molecular glioblastoma subtypes,
with an enrichment of PD-L1 low specimens in the proneural
and G-CIMP subtypes and PD-L1 high specimens in the mesen-
chymal subtype. These results are well in line with some previ-
ous studies showing evidence for increased immunological
activity in mesenchymal glioblastomas and may be explained
by an interaction of PD-L1 with signal transducer and activator
of transcription 3 (STAT3). STAT3 has been shown to be a major
promoter of PD-L1 expression that is upregulated in mesenchy-
mal glioblastomas.11,47 – 50 Based on our findings, clinical stud-
ies with PD1/PD-L1 inhibitors need to include investigation of
differential response patterns across molecular glioblastoma
subtypes.
Studies on the prognostic impact of tumoral PD-L1 expres-
sion have shown inconsistent results across tumor
types.20,51 – 53 In our series including a total of 563 glioblastoma
cases from 2 independent cohorts, there was no association of
PD-L1 expression with patient outcome. In particular, the prog-
nostic impact of neuronal PD-L1 protein expression recently,
which was described in a very small series of 17 glioblastoma
cases, was not corroborated in our series of 117 specimens
from the Vienna retrospective cohort.19 We acknowledge that
the power of survival analyses in our series is limited by the
sample size and the retrospective study design, and our results
surely need confirmation in larger and prospectively collected
cohorts. However, the known prognostic factors of patient
age, Karnofksy performance status, extent of resection, and
MGMT promoter methylation status showed the expected sep-
aration of prognostic groups and thus validate the suitability of
our cohort for exploratory survival analyses.
In conclusion, this analysis shows that PD1 and/or PD-L1 are
immunohistochemically detectable in a majority of glioblasto-
ma samples, thus suggesting that the immunosuppressive
PD1/PD-L1 axis is active in glioblastoma. A clinical study with
specific immune checkpoint inhibitors is warranted in glioblas-
toma, and it remains to be seen whether PD-L1 expression pat-
terns or molecular glioblastoma subtypes will correlate with
response to such treatments.
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